Volume 39, Issue 2 , Pages 245-256, February 2002
Nutritional status in the HEMO study cohort at baseline☆☆☆★
Abstract
The nutritional status of the first 1,000 patients randomized into the Hemodialysis (HEMO) Study was analyzed at baseline when they received their typical dialysis dose (equilibrated Kt/V = 1.30 ± 0.22) and dialysis membrane. This is the largest study to date of the nutritional status of chronic hemodialysis patients. The mean (±SD) values for these parameters included a serum albumin level of 3.65 ± 0.38 g/dL, a dietary energy intake of 22.9 ± 8.4 kcal/kg/day, a dietary protein intake of 0.93 ± 0.36 g/kg/day, and a double pool normalized protein catabolic rate (enPCR) of 1.00 ± 0.25 g/kg/day. The percentage of patients below HEMO Study nutritional standards of care included 29% of patients with a serum albumin level less than 3.5 g/dL, 76% of patients with a dietary energy intake less than 28 kcal/kg/day, 61% of patients with a dietary protein intake less than 1.0 g/kg/day, and 52% of patients with an enPCR of less than 1.0 g/kg/day. There was a strong correlation between dietary protein intake and dietary energy intake (r = 0.74, P < 0.0001). Significant correlations were also evident between serum albumin and double pool PCR and between dietary protein intake and double-pool PCR. Kt/V and membrane flux were not predictive of baseline dietary protein intake, dietary energy intake, or serum albumin level. Thus, a majority of patients in the HEMO Study had protein and energy intake levels and enPCR levels that were below National Kidney Foundation Kidney Dialysis Outcome Quality Improvement (NKF-K/DOQI) guidelines. © 2002 by the National Kidney Foundation, Inc.
Keywords: Nutrition, energy intake, protein intake, serum albumin, protein catabolic rate, clinical trial
To access this article, please choose from the options below
☆ The HEMO Study is supported by grants from the National Institute of Digestive and Kidney Disease. Some study dialyzers have been provided by Baxter Healthcare Corporation (McGaw Park, IL) and Fresenius Medical Care-North America (Lexington, MA). Nutritional supplements have been provided by Ross Laboratories (Columbus, OH) and vitamins by R&D Labs, Inc. (Marina del Ray, CA). Dr. Rocco was supported by National Institutes of Health grant #5 U01 DK49271.
☆☆ Address reprint requests to Michael V. Rocco, MD, MSCE, Wake Forest University School of Medicine, Department of Internal Medicine/Nephrology, Medical Center Blvd, Winston-Salem, NC 27157-1053. E-mail: mrocco@wfubmc.edu
★ 0272-6386/02/3902-0002$35.00/0
PII: S0272-6386(02)37568-1
© 2002 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Volume 39, Issue 2 , Pages 245-256, February 2002
